Abstract
The pertinence to clinical practice of various classifications of human lymphoproliferative disease revolves around whether these arbitrary delineations of tumour properties are predictive either for disease behaviour or responsiveness to various therapeutic modalities and thus prognosis. In this regard the morphologic scheme for non Hodgkin’s lymphoma proposed by the modified Rappaport classification (1) and the utilization of cellular properties which denote the immunologic derivation of tumour cells (2) have both yielded useful frameworks which have clinical utility. To these assessments have recently been added cellular purine and pyrimidine enzymic profiles. These appear to complement the established markers for these disorders but more importantly may have potential therapeutic significance for the use of selective therapy such as adenosine deaminase and purine nucleoside Phosphorylase inhibition (3–5) or the in vivo use of nucleosides such as thymidine (6,7).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C.W. Berard and R.F. Dorfman. Histopathology of malignant lymphomas. Clin. Haematol. 3: 39 (1976).
C.D. Bloomfield, J. Gajl-Peczalska, G. Frizzera, J.H. Kersey and A.I. Goldman. Clinical utility of lymphocytic surface markers combined with Lukes-Collins histologic classification in adult lymphoma. N. Eng. J. Med. 301: 512 (1979).
C.A. Koller, B.S. Mitchell, M.R. Grever, E. Mejias, L. Malspeis and E.N. Metz. Treatment of acute lymphoblastic leukemia with 2 deoxycoformycin. Clinical and biochemical consequences of adenosine deaminase inhibition. Cancer Treat. Reports 63: 1949 (1979).
H.G. Prentice, J.F. Smyth, K. Ganeshaguru, B. Wonke, K. Bradstock, G. Janossy, A. Goldstone and A.V. Hoffbrand. Remission induction with the adenosine deaminase inhibitor 2′deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet ii, 170 (1980).
I.S. Kazmers, B.S. Mitchell, P.E. Daddona, L.L. Wotring, L.B. Townsend and W.N. Kelley. Inhibition of purine nucleoside Phosphorylase by 8 aminoguanosine: Selective toxicity for T lymphoblasts. Science 214: 1137 (1981).
B. Howell, B. Chu, J. Mendelsohn, D.A. Carson, F.H. Kung and J.E. Seegmiller. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic and biochemical studies in a patient with T-cell acute lymphocytic leukemia. J. Natl. Cane. Inst. 65: 277 (1980).
D.W. Kufe, P. Beardsley, D. Karp, L. Parker, A. Rosowsky, G. Canellos and E. Frei. High-dose thymidine infusions in patients with leukemia and lymphoma. Blood 55: 580 (1980).
P.H. Ellims, M.B. Van Der Weyden and G. Medley. Thymidine kinase isoenzymes in malignant lymphoma. Cancer Res. 41: 691 (1981).
P.H. Ellims, T.E. Gan, G. Medley and M.B. Van Der Weyden. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin’s lymphomas. Blood 58: 926 (1981).
P.H. Ellims, T.E. Gan and M.B. Van Der Weyden. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br. J. Haematol.49: 479 (1981).
R.M. Fox, S.K. Piddington, E.H. Tripp, N.P. Dudman and M.H.N. Tattersall. Thymidine sensitivity of cultural leukemic lymphocytes. Lancet 2: 391 (1979).
R.H. Zielke. Isolation of thymidine-resistant cells from a thymidine-sensitive acute lymphoblastic cell line. Cancer Res. 39: 3373 (1979).
T.E. Gan, L. Hallam, G.R. Pilkington and M.B. Van Der Weyden. A rapid and simple radiometric assay for thymidine phosphorylase of human peripheral blood cells. Clin. Chim. Acta. 116: 231 (1981).
H.J. Meuwissen, B. Pollara. Combined immunodeficiency and inborn errors of purine metabolism. Blut 37: 173 (1978).
E.R. Giblett, A.J. Amman, D.W. Wara, R. Sandman and L.K. Diamond. Nucleoside Phosphorylase deficiency in a child with severely defective T cell immunity and normal B cell immunity. Lancet 1: 1010 (1975).
W.D. Biggar, E.R. Giblett, R.L. Ozere and D.B. Grover. A new form of nucleoside Phosphorylase deficiency in two brothers with defective T cell function. J. Pediatr. 92: 354 (1978).
B.S. Mitchell, E. Mejias, P.E. Daddona and W.N. Kelley. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc. Natl. Acad. Sci. USA. 75: 5011 (1978).
M.B. Van Der Weyden and L. Bailey. A micromethod for determining adenosine deaminase and purine nucleoside Phosphorylase activity in cells from human peripheral blood. Clin. Chim. Acta. 82: 179 (1978).
H. Ludwig, R. Kuzmits, H. Pietschmann and M.M. Muller. Enzymes of the purine interconversion system in chronic lymphocytic leukaemia: decreased purine nucleoside Phosphorylase and adenosine deaminase activity. Blut 39: 309 (1979).
J. Blatt, G.H. Reaman, H. Levin and D.G. Poplack. Purine nucleoside Phosphorylase activity in acute lymphoblastic leukemia. Blood 56: 380 (1981).
I. Ben-Basset, F. Simoni, F. Holtzman and B. Ramot. Adenosine deaminase activity of normal and leukemic cells. Israel J. Med. Sci. 15: 925 (1980).
K. Ganeshaguru, N. Lee, P. Llewellin, H.G. Prentice, A.V. Hoffbrand, D. Catovsky, J.A. Haveshav, J. Robinson and M.F. Greaves. Adenosine deaminase concentration in leukaemia and lymphoma: relationship to cell phenotypes. Leukaemia Res. 5: 215 (1981).
J.F. Smyth, D.G. Poplack, B.J. Holman, B. Leventhal and G. Jarbro. Correlation of adenosine deaminase with cell surface markers in acute lymphoblastic leukaemia. J. Clin. Invest. 59: 710 (1978).
F. Ambrogi, B. Grassi, S. Ronca-Testoni and G. Ronca. Blood lymphocytes in chronic lymphocytic leukaemia and Hodgkin’s disease: immunological features and enzymes of nucleoside metabolism. Clin. Exp. Immunol. 28: 80 (1977).
B. Ramot, F. Brook-Simoni, N. Barnea, O. Bank and F. Holtzman. Adenosine deaminase in lymphocytes of normal individuals and patients with chronic lymphocytic leukaemia. Br. J. Haematol. 36: 67 (1977).
T.E. Gan, L. Hallam and M.B. Van Der Weyden. Purine and pyrimidine activities in acute and chronic lymphocytic leukaemia: relation to cellular proliferative status. Leukemia Research (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media New York
About this chapter
Cite this chapter
Van Der Weyden, M.B., Hallam, L., Gan, T.E., Ellims, P.H. (1984). Purine and Pyrimidine Enzyme Markers in Human Lymphoid Malignancies. In: De Bruyn, C.H.M.M., Simmonds, H.A., Müller, M.M. (eds) Purine Metabolism in Man-IV. Advances in Experimental Medicine and Biology, vol 165. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0390-0_47
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0390-0_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0392-4
Online ISBN: 978-1-4757-0390-0
eBook Packages: Springer Book Archive